Article
Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting.
BMC cancer - 25 May 2021
Wang Qianqian, Gao Wen, Gao Fangyan, Jin Shidai, Qu Tianyu, Lin Fan, Zhang Chen, Zhang Jingya, Zhang Zhihong, Chen Liang, Guo Renhua
Abstract excerpt
BACKGROUND: To compare the benefits and explore the cause of acquired resistance of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and its combination with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients harboring EGFR mutation in a real-life setting. METHODS: This retrospective analysis included 117 advanced NSCLC patients with EGFR mutation who underwent...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.